

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

VOLUNTARY ANNOUNCEMENT INCREASE IN REGISTERED SHARE CAPITAL OF A SUBSIDIARY

This announcement is made by the board of directors (the “**Board**”) of Concord Healthcare Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Board is pleased to announce that on November 25, 2024, Beijing Healthingkon Technology Co., Ltd. (北京和信康科技有限公司), a subsidiary controlled by the Company, has entered into a capital increase agreement (the “**Series B Investment Agreement**”) with its current shareholders (including the Company and Healthingkon Investment Holding Limited (和信康投資控股有限公司) (“**Healthingkon Investment**”) and Hainan Yiling Medical Industry Development Co., Ltd. (海南一齡醫療產業發展有限公司) (“**Yiling Group**”). Pursuant to the Series B Investment Agreement, the Company, Yiling Group and Healthingkon Investment have agreed to subscribe for an aggregate of the registered capital of RMB5,404,765 of Beijing Healthingkon at a total consideration of RMB91.0 million (the “**Series B Investment in Beijing Healthingkon**”).

Upon the completion of Series B Investment in Beijing Healthingkon, the Company, Yiling Group and Healthingkon Investment will beneficially hold 27.02%, 4.60% and 21.71% of the registered capital of Beijing Healthingkon, respectively. Beijing Healthingkon will remain as a controlled subsidiary of the Company and its financial performance will be consolidated to the consolidated financial statements of the Company.

To the best knowledge of the Company, Yiling Group and Healthingkon Investment are independent from the Company, directors, controlling shareholders and substantial shareholders of the Company. The Series B Investment in Beijing Healthingkon is not a connected transaction under Chapter 14A of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Furthermore, as all of the applicable percentage ratios (as defined in the Listing Rules) in respect of the Series B Investment in Beijing Healthingkon pursuant to the relevant Series B Investment Agreement is less than 5%, the Series B Investment in Beijing Healthingkon is not subject to any notification and announcement requirement as set out in Chapter 14 of the Listing Rules and not subject to the approval of the shareholders of the Company.

Beijing Healthingkon is an AI-orientated company. The Company will continue to invest in the fields of AI and looks forward to working with more business partners to compel the vigorous development of medical AI technologies. See “History, Development and Corporate Structure – Acquisitions, Investments and Disposals – Acquisition of Beijing Healthingkon” in the prospectus of the Company dated December 29, 2023 for more information of Beijing Healthingkon’s business.

Shareholders and potential investors of the Company are advised to exercise due care when dealing in the Shares of the Company.

By Order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the People’s Republic of China, November 25, 2024

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. CHEN Hongzhang and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.